Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMLTAES)

Drug Name
MK-0752 Drug Info
Synonyms
MK-0752; 471905-41-6; MK0752; UNII-9JD9B4S53T; MK 0752; cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexanepropanoic acid; 9JD9B4S53T; 3-((1r,4s)-4-((4-chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-(cis-4-((4-Chlorophenyl)sulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 3-((1r,4s)-4-(4-chlorophenylsulfonyl)-4-(2,5-difluorophenyl)cyclohexyl)propanoic acid; 952578-68-6; cc-14; C21H21ClF2O4S; MLS006011072; SCHEMBL756249; SCHEMBL756248; SCHEMBL756247; CHEMBL3392635
Cross-matching ID
PubChem CID
9803433
CAS Number
CAS 471905-41-6
TTD Drug ID
D02HNG

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Spliceosome 2.04 0.00e+0 101/150 (67.33%) HSPA8;SRSF5;HNRNPA3;...
Retinol metabolism 1.98 4.24e-3 41/68 (60.29%) UGT2B28;ADH1B;UGT2B4;...
Fanconi anemia pathway 1.96 2.83e-3 36/54 (66.67%) FANCI;FANCA;REV3L;...
Propanoate metabolism 1.92 4.24e-3 30/34 (88.24%) ABAT;ALDH6A1;ACACB;...
Cell cycle 1.76 3.56e-2 110/124 (88.71%) E2F2;SMC1A;CDC7;...
Drug metabolism 1.75 3.54e-2 78/151 (51.66%) UGT2B28;ADH1B;FMO1;...
DNA replication 1.73 3.27e-2 34/36 (94.44%) LIG1;MCM3;MCM5;...
Porphyrin and chlorophyll metabolism 1.73 2.97e-2 23/43 (53.49%) UGT2B28;CP;UGT2B4;...
RNA transport 1.73 2.73e-2 128/186 (68.82%) PNN;NUP210;TARDBP;...
Fat digestion and absorption 1.71 3.14e-2 35/43 (81.4%) APOA1;FABP1;APOB;...
One carbon pool by folate 1.71 2.93e-2 15/20 (75%) TYMS;MTHFD1;SHMT1;...
Mismatch repair 1.71 2.69e-2 22/23 (95.65%) LIG1;MSH6;RFC1;...
Valine, leucine and isoleucine degradation 1.69 2.55e-2 42/48 (87.5%) ABAT;HMGCS2;ALDH6A1;...
Homologous recombination 1.69 2.36e-2 35/41 (85.37%) RAD54L;BRCA1;BARD1;...
Ascorbate and aldarate metabolism 1.66 3.96e-2 15/30 (50%) UGT2B28;UGT2B4;GUSB;...
Pentose and glucuronate interconversions 1.64 4.67e-2 17/34 (50%) UGT2B28;UGT2B4;GUSB;...
Huntington disease -1.68 2.08e-2 233/306 (76.14%) DNAH6;COX8A;PSMD7;...
Renal cell carcinoma -1.69 2.14e-2 68/69 (98.55%) PAK5;RBX1;MAPK3;...
Parkinson disease -1.70 1.85e-2 176/249 (70.68%) COX8A;SLC6A3;PSMD7;...
Antigen processing and presentation -1.70 1.84e-2 60/78 (76.92%) PSME1;KLRD1;B2M;...
Natural killer cell mediated cytotoxicity -1.71 1.74e-2 99/131 (75.57%) CD244;KLRD1;MAPK3;...
Necroptosis -1.72 1.63e-2 113/159 (71.07%) BID;PYGL;RBCK1;...
Phagosome -1.73 1.65e-2 118/152 (77.63%) FCGR2A;RAB7A;TLR2;...
Epstein-Barr virus infection -1.76 1.28e-2 189/202 (93.56%) BID;SAP30L;HDAC2;...
Malaria -1.76 1.28e-2 44/50 (88%) ITGB2;ICAM1;TGFB2;...
Non-alcoholic fatty liver disease -1.76 1.29e-2 126/155 (81.29%) NDUFA8;SDHC;EIF2AK3;...
Pathogenic Escherichia coli infection -1.76 1.35e-2 152/197 (77.16%) CTTN;ARF6;IRAK4;...
IL-17 signaling pathway -1.79 1.07e-2 84/94 (89.36%) MAPK3;CCL7;CSF2;...
Leishmaniasis -1.80 1.00e-2 67/77 (87.01%) FCGR2A;TLR2;MAPK3;...
NOD-like receptor signaling pathway -1.82 7.30e-3 145/181 (80.11%) RIPK1;MAPK3;ATG12;...
Endocytosis -1.86 4.23e-3 198/252 (78.57%) RAB4A;ARPC1A;CAPZA2;...
Hematopoietic cell lineage -1.87 3.76e-3 90/99 (90.91%) CD5;HLA-DRB1;CD8B;...
Mitophagy -1.88 3.22e-3 56/68 (82.35%) RAB7A;ULK1;TAX1BP1;...
Viral myocarditis -1.89 2.60e-3 53/60 (88.33%) CASP8;CD86;HLA-DOB;...
Type I diabetes mellitus -1.90 2.82e-3 38/43 (88.37%) HLA-DPB1;CD80;GZMB;...
TNF signaling pathway -1.91 2.05e-3 103/112 (91.96%) CSF2;CREB3L1;FADD;...
Rheumatoid arthritis -1.92 1.13e-3 78/93 (83.87%) HLA-DPB1;IL6;CD80;...
Shigellosis -1.94 1.25e-3 180/246 (73.17%) RBX1;MAPK3;ATG12;...
Cell adhesion molecules -1.96 1.41e-3 118/148 (79.73%) ITGAM;CLDN1;ITGA8;...
Allograft rejection -1.99 1.61e-3 32/38 (84.21%) HLA-DPB1;CD80;GZMB;...
Autoimmune thyroid disease -2.00 1.88e-3 46/53 (86.79%) HLA-DPB1;CD80;GZMB;...
Fluid shear stress and atherosclerosis -2.05 2.26e-3 123/139 (88.49%) RELA;MMP2;MAPK13;...
Yersinia infection -2.05 2.82e-3 120/137 (87.59%) MAPK3;RAC1;BAIAP2;...
Salmonella infection -2.07 3.76e-3 198/249 (79.52%) RAB7A;TLR2;RIPK1;...
Bacterial invasion of epithelial cells -2.10 5.64e-3 59/77 (76.62%) RAC1;ACTR3;ARPC1A;...
Graft-versus-host disease -2.28 0.00e+0 32/42 (76.19%) HLA-DPB1;IL6;CD80;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
Fibrocystic breast disease
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A (Parent) CVCL_0598 Homo sapiens 1.11uM - 10uM 3H, 6H, 12H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 3H, 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H